Notable Labs Ltd (Notable Labs), formerly Vascular Biogenics Ltd, operates as a provider of biopharmaceutical products. The company discovers, develops and commercializes gene therapy medicines for the treatment of cancer and inflammatory diseases. Its lead product candidate VB-111, a gene-based biologic agent is developed to treat recurrent glioblastoma, colon, ovarian, thyroid cancer and solid tumors. Its pipeline products include VB 201 and VB 703, oral small molecules being developed through lecinoxoids platform for treating cardiovascular diseases, liver and renal fibrosis. Vascular Biogenics uses its proprietary vascular targeting system technology to enable the systemic administration of gene therapy and improve angiogenic blood vessels. The company is investigating its VB-600 platform targeting MOSPD2 for treating cancers and inflammatory diseases. Notable Labs is headquartered in Modiin, Tel Aviv, Israel.
Headquarters
United States of America
Address
320 Hatch Drive, Foster City, California, 94404
Website
notablelabs.com
Telephone
1 415 8512410
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NTBL (NASD)
Revenue (2022)
$310,000
-52.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
65.1%
(2022 vs 2021)
Market Cap*
$8.3M
Net Profit Margin (2022)
XYZ
26.0%
(2022 vs 2021)
* As of and is in US$
Notable Labs Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline Programs: | Vascular Targeting System (VTS) |
| VB601- | VBL Therapeutics |
| VB-111 - Thyroid Cancer, Ovarian Cancer and Solid Tumors | Vascular Biogenics |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Asset Disposal | In March, the company sold its manufacturing facility in Modi’in, Israel, and certain related assets to Aleph Farms for US$7.1 million. |
| 2023 | Contracts/Agreements | In February, the company entered into a merger agreement with VBL Therapeutics, a biotechnology company. |
| 2023 | Contracts/Agreements | In February, the company entered into a merger agreement with Notable Labs Inc. |
Competitor Comparison
| Key Parameters | Notable Labs Ltd | Taro Pharmaceutical Industries Ltd | Champions Oncology Inc | BioLineRx Ltd | Accelerated Evolution Biotechnologies Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Israel | United States of America | Israel | Israel |
| City | Foster City | Haifa | Baltimore | Modiin | Ness Ziona |
| State/Province | California | - | Maryland | - | Sharon (Netanya) |
| No. of Employees | 16 | 1,554 | 230 | 79 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marc Kozin | Chairman | Executive Board | 2020 | 60 |
| Dror Harats | Chief Executive Officer; Director | Executive Board | 2000 | 65 |
| Sam Backenroth | Chief Financial Officer | Senior Management | 2021 | - |
| Erez Feige, Ph.D. | Senior Vice President - Business Operations | Senior Management | 2006 | 48 |
| Matthew Trudeau | Chief Commercial Officer | Senior Management | 2022 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer